Homologous and Heterologous Covid-19 Booster Vaccinations | NEJM
Heterologous COVID-19 booster doses show 68 percent effectiveness
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses | The BMJ
Covid-19 vaccine mixing: could heterologous boosters improve immunity?
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study - The Lancet Global Health
Explained | What is a heterologous booster vaccine, and what are its advantages? - The Hindu
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination | Nature Medicine
Covovax booster dose: DGCI approves Covid-19 vaccine Covovax as heterologous booster dose - The Economic Times
NTAGI holds meeting on Covovax inclusion as heterologous booster on CoWin portal, ET HealthWorld
A 'mix and match' approach to SARS-CoV-2 vaccination | Nature Medicine
iNCOVACC World's first Intranasal Vaccine to receive both Primary series & Heterologous booster approval | DD News
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet
Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2 | Nature Communications
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - The Lancet
Study shows enhanced immunogenicity of heterologous boosting strategy in individuals primed with J&J vaccine
RACGP - Does mixing COVID boosters provide better immunity?
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination | Nature Medicine
PSMID Statement on Heterologous Vaccination and Booster Doses for COVID-19 for the General Population -
EU Medicines Agency on X: "‼️ EMA & @ECDC_EU share their recommendations on the possibility of using 2 different #COVID19vaccines, either for the 1st and 2nd doses of a primary course, or
Is the advantage conferred by the heterologous regimen conserved after a booster dose of mRNA-based COVID-19 vaccine?
Effectiveness of CoronaVac, AZD1222, and BNT162b2 vaccine boosters
Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study | The BMJ
